Budget Impact Analysis of 68-Ga-PSMA-11 PET CT Imaging Followed by 177Lu-PSMA-617 Therapy in Metastatic Castrate-Resistant Prostate Cancer

Author(s)

Parinita Barman, MPH1, Amit Gupta, MSc1, George Papadopoulos, BSc (Hons)2, Michael Aristides, MSc2, Hemant Rathi, MSc1.
1Skyward Analytics, Gurugram, India, 2Lucid Health Consulting, Sydney, Australia.
OBJECTIVES: 68Ga-PSMA-11 is a radiotracer for early detection of prostate-specific membrane antigen (PSMA)-expressing cells, while 177Lu-PSMA-617 is a radioligand therapy that targets these cells. A budget impact analysis (BIA) was conducted from an Australian healthcare perspective to estimate total healthcare expenditures of introducing 68Ga-PSMA-11 PET/CT imaging followed by 177Lu-PSMA-617 for patients with metastatic castrate resistant prostate cancer (mCRPC) in Australia.
METHODS: An Excel-based BIA with a six-year time horizon was developed to project the overall healthcare expenditure. An epidemiological approach was employed to estimate eligible patients for 68Ga-PSMA-11 PET/CT imaging. Model inputs were sourced from Australian public databases and published literature, with costs adjusted to 2024 Australian dollars. This BIA also includes the associated subsequent treatment costs to estimate the impact of the change in use of other health technologies more comprehensively.
RESULTS: According to Australian Bureau of Statistics, an estimated 3,853 patients were eligible for 68Ga-PSMA-11 PET/CT imaging in Year 1, increasing to 4,134 in Year 6, based on an annual growth rate of 1.4%. A utilisation rate of 25% was applied in Year 1, increasing to 50.3% by Year 6 (relative annual increase of 15%). It was assumed that 90% of these patients proceed to 177Lu-PSMA-617 therapy. At a unit cost of $1,400 for 68Ga-PSMA-11 PET/CT imaging and $8,000 for 177Lu-PSMA-617 therapy, total combined cost to Department of Health would be $32.5M in Year 1, increasing to $70.4M by Year 6, with a cumulative six-year expenditure of $297M
CONCLUSIONS: Introducing ⁶⁸Ga-PSMA-11 PET/CT for mCRPC in Australia may involve upfront costs, but it offers significant clinical benefits. By accurately identifying patients suitable for radionuclide therapy, it enables earlier and more targeted treatment, improves quality of life, and avoids unnecessary exposure to costly and potentially ineffective therapies. This targeted approach may result in long-term savings and is now reimbursed on the MBS in Australia.

Conference/Value in Health Info

2025-11, ISPOR Europe 2025, Glasgow, Scotland

Value in Health, Volume 28, Issue S2

Code

EE80

Topic

Economic Evaluation, Medical Technologies

Topic Subcategory

Budget Impact Analysis

Disease

Genetic, Regenerative & Curative Therapies, Oncology, Personalized & Precision Medicine

Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×